News from Arrotek

Arrotek Co-Founder Mark Pugh Named CEO of Theragenics Corporation

Arrotek Co-Founder Mark Pugh Named CEO of Theragenics Corporation

by Arrotek Medical Ltd

Arrotek’s Co-Founder, Mark Pugh, has been appointed as CEO of Theragenics Corporation, the US-based parent company of Arrotek. The Theragenics Corporation includes the brands Theragenics, Arrotek, Galt, and NeedleTech. It specialises in the supply, design, and manufacture of minimally invasive medical devices.

Mr Pugh succeeds Frank Tarallo who retired at the end of 2023 following a decade leading the Theragenics Corporation.

Mr Pugh said: “I am deeply passionate about Theragenics’ mission of delivering life-changing minimally invasive medical solutions. This company possesses a robust foundation, innovative products, and a diversified portfolio of capabilities across multiple growing therapeutic areas.”

Strong Medical Device Industry Track Record

Mr Pugh co-founded Arrotek along with Ger O’Carroll in 2005 in Sligo, Ireland to provide minimally invasive medical device design and manufacturing services. Specialising in interventional and diagnostic catheters, the company grew consistently over the years and today has over 100 employees with design, engineering, and manufacturing facilities in Ireland as well as Massachusetts in the USA.

Arrotek’s customers in Europe, the USA, and around the world include startups, established medical device companies, and global corporations.

Mr Pugh also oversaw the acquisition of Arrotek by the Theragenics Corporation in 2019. He previously served as President of the OEM Group, leading the design and contract manufacturing divisions of the business, before being appointed as Theragenics Group CEO.

Global Leading Corporation

Through its brands and subsidiaries, Theragenics Corporation provides products, services, and solutions to companies in the medical device industry as well as clinicians and healthcare providers. It is a global leader in fields ranging from brachytherapy to interventional radiology to interventional cardiology to vascular surgery.

Mr Pugh said: “I am thrilled to collaborate with our exceptional leadership team and board of directors to propel Theragenics to new heights, cultivate a culture of innovation, optimise operational efficiencies, and ultimately enhance the value we deliver to medical device industry customers, clinicians, healthcare providers, and, most importantly, the patients we serve.”

Share this post: